Every laboratory informatics market report published in the past year tells roughly the same growth story: adoption is rising, the market is expanding, and the direction of travel is unmistakable. What those same reports rarely dwell on is what happens in the months after a laboratory actually signs the contract.
Start with the numbers, because they matter and because they deserve honest framing rather than either dismissal or uncritical repetition. Market analysis places the Indian LIMS market at approximately USD 111.8 million in 2025, projected to grow to roughly USD 217.9 million by 2033 — a trajectory broadly consistent with the global LIMS market’s own projected path from about USD 2.08 billion to USD 3.48 billion over the same period. These are useful directional figures. They are also, worth saying plainly, projections from a single market-analysis source rather than measured, audited adoption data, and should be read as an informed estimate of where the market is heading rather than a precise account of where it currently stands.
What the growth curve doesn’t capture is what happens operationally once a laboratory commits to modernising its systems — and this is where the more useful, more honest part of the story lives.
The Part Vendors Don’t Lead With
Across several independent laboratory-informatics implementation guides published in 2026 — not from a single vendor, but converging consistently across separate consultancies — one pattern recurs with striking regularity: roughly three out of four laboratories report persistent integration problems after LIMS deployment, and the root cause, in the assessment of implementers who work through these projects repeatedly, is rarely the software itself. It’s that the laboratory wasn’t operationally ready for it. A separate figure from the same body of implementation guidance found that close to 29% of laboratories cite staff resistance specifically as a top barrier to digitalisation — a thread this Cover Story picks up in more depth in the next section.
The single most consistently underestimated cost in any LIMS implementation, according to laboratory-informatics consultancy Astrix, is data migration itself — moving a laboratory’s existing records, method logic, and historical results out of legacy systems and into the new one. This sounds like a mechanical, solvable problem. In practice, it is frequently where projects go over budget and over schedule, because static and dynamic legacy data both require extraction, translation, and validated loading, and the translation step in particular is almost always a bigger undertaking than initial project scoping assumes.
Where This Actually Bites: The Undocumented Mapping Problem
The specific failure pattern is worth naming precisely, because “integration is hard” is too vague to be useful. Laboratory migration specialists describe a consistent culprit: instrument middleware that fails not because the new system is poorly built, but because the original mapping between an instrument and the software reading its output was never properly documented in the first place. An instrument installed years earlier might be feeding data through a connection someone configured once and never wrote down — a mapping that no current employee necessarily understands or can reconstruct. The recommended safeguard, according to laboratory migration guidance, is to trace one full result end-to-end, from the instrument itself through to the final certificate of analysis, before assuming any migration plan is safe to execute. Accounting and invoicing integrations fail for a related reason: the logic connecting a LIMS to a laboratory’s billing systems often gets duplicated across both platforms and quietly drifts out of sync over time, invisible until someone reconciles the numbers and finds they don’t match.
Why This Isn’t Just an IT Problem
Here is the point where this section connects directly back to the regulatory stakes established earlier in this Cover Story. A specification error introduced during a LIMS migration in a pharmaceutical context is not simply an inconvenience to be fixed on the next sprint. According to laboratory modernisation specialists working specifically in pharma and biotech migrations, two distinct failure modes follow directly from a migration error: a false fail, where a product is incorrectly flagged as out of specification against criteria it should have passed, triggering unnecessary investigations and direct revenue loss on products that were never actually defective; and a more serious regulatory discrepancy, where a certificate of analysis’s content differs from the historical record it’s meant to match — creating exactly the kind of audit-trail inconsistency that constitutes a data-integrity finding under the ALCOA+ framework this Cover Story examines in detail in its regulatory section. In other words: a migration error in a regulated laboratory doesn’t stay a technical problem. It becomes a compliance event.
The Honest Summary
None of this is an argument against modernisation — the direction of travel toward connected, integrated laboratory systems is real, and the previous two sections of this Cover Story have already laid out why that direction is structurally sound. It is an argument against treating adoption figures as the whole story. A market-size projection tells you where the industry is heading. It tells you nothing about whether any individual laboratory’s migration will go smoothly, and the evidence gathered here suggests that, more often than not, it doesn’t — not because the technology fails, but because the operational discipline required to move legacy data safely is consistently underestimated at the planning stage. For a laboratory evaluating a LIMS or ELN investment, that is arguably the more useful number to internalise than the market’s projected compound annual growth rate.
– Rajesh Kumar Desetti
